- Open Access
The economic and personal burden of cluster headache: a controlled cross-sectional study
The Journal of Headache and Pain volume 23, Article number: 58 (2022)
Cluster headache is a less-prevalent primary headache disorder but is overrepresented with regards to use of health care and social services. More insight into the socioeconomic impact is required.
We investigated both the personal and societal disease burden and cost in 400 patients with well-classified cluster headache according to the ICHD-criteria and 200 sex- and age matched controls. All participants completed a cross sectional questionnaire and semi-structured interview.
Patients with chronic cluster headache constituted 146 out of 400 (37%). Overall, restriction in personal and/or professional life was reported by 94% of patients during attack periods. Even in remission, nine times as many episodic patients rated their health as poor/very poor compared to controls (9% vs 1%, p = 0.002). For chronic patients, the odds of rating health as good/very good were ten times lower compared to controls (OR:10.10, 95%CI:5.29–18.79. p < 0.001) and three times lower compared to episodic patients in remission (OR:3.22, 95%CI:1.90–5.47, p < 0.001). Additionally, chronic cluster headache patients were 5 times more likely to receive disability pension compared to episodic (OR:5.0, 95%CI:2.3–10.9, p < 0.001). The mean direct annual costs amounted to 9,158€ and 2,763€ for chronic and episodic patients, respectively (p < 0.001). We identified a substantial loss of productivity due to absence from work resulting in a higher indirect cost of 11,809 €/year/patient in the chronic population and 3,558 €/year/patient in the episodic population. Presenteeism could not be quantified but productivity was reduced in patients by 65% in periods with attacks compared to controls.
Cluster headache has a major negative impact on personal life, self-perceived health, and societal cost. Patients with the chronic variant are vastly more burdened. Patients with the episodic form were still markedly affected during the remission period. This study highlights the need for more effective therapy to lighten the burden on patients and society.
The majority of the cluster headache (CH) population is episodic (eCH) and experience attacks in bouts, thus being in remission for months to years [1, 2]. The remission period relieves the patients of the severe pain and may also ease known comorbidities, such as depression and anxiety . Yet, it has been reported that avoidance behavior and worries about future attacks continue throughout the remission period  and for many patients sleep disturbances persist outside the bout[2, 5]. In addition, CH-related symptoms such as shadow attacks (a mild pain attack that resembles a CH attack but is short-lasting and less intense) and solitary attacks are not uncommon during remission . This raises the question whether CH patients in remission can be regarded as “healthy” or as sufferers from a chronic disease with some symptoms manifesting cyclically and others permanently. Therefore, our first hypothesis was that eCH patients in remission were more burdened compared to controls. Anecdotally, CH tends to abate over time  but clinically, usually lasts for at least several decades with an early age of onset typically in the third decade . This combination of early onset and long-term disease duration have enormous potential to impact both the individual, with regards to life choices in family and professional matters, but also the society in terms of direct and indirect costs. Per definition, chronic CH (cCH) patients do not go into meaningful remission periods  and intuitively this group should be more burdened by the disease. Overall, the literature supports this notion, however, a recent review concludes that the current evidence level is too sparse to draw firm conclusions . Our second hypothesis was therefore that cCH patients were more burdened in personal life and costs compared to eCH patients.
We aimed to explore the impact on both personal and societal parameters to compile a comprehensive assessment of the disease burden in a large cohort of eCH and cCH patients compared to controls.
The data was obtained from the Danish Cluster Headache Survey, which is a cross-sectional questionnaire study. Data collection was performed between 2012 and 2017. The publication on the primary analysis describes the methodology in details  and succeeding publications [11,12,13,14,15,16] are based on the same methodology.
In total 600 participants, 400 CH patients and 200 controls contributed to the study (Fig. 1). Patients were diagnosed with CH according to the International Classification of Headache Disorders (ICHD) II edition and all diagnoses were validated by a headache specialist at the Danish Headache Center. Patients suspected to have an underlying condition causing the CH or having another chronic headache disorder were excluded. Inclusion of a patient with a comorbid episodic headache required ability to distinguish CH attacks from other headache attacks. Recruitment was mainly based at the Danish Headache Center, however, a few patients were recruited from private neurologists and from online advertisements. Controls were matched for age and sex and allowed to have headache up to one day/month. All participants were fluent in Danish and between 18–65 years.
The questionnaire consisted of 365 questions that were subdivided into seven sections . Ambiguities and missing data were clarified by the succeeding semi-structured interview by a physician, trained medical student or study nurse (MB, NL, MF, AP).
Regarding the personal burden of CH, we investigated three different domains: social, family and professional life. All questions included in this study were developed by authors MB and RJ based on previous epidemiological headache questionnaires [17, 18]. Self-rated health and wellbeing were rated on a five-level scale: Very good, good, neither poor nor good, poor or very poor. Participants were asked if they received fulltime or part-time disability pension and if they received full-time disability pension, whether it was based on their CH diagnosis. Ability to work was rated on an eleven-point rating scale (0 being not reduced and 10 being completely reduced) in periods with attacks for CH patients and controls were asked to rate their work productivity in general. Patients were asked when they experienced their first attack, and this defined the onset of CH.
The direct cost of CH was calculated as the sum of self-reported use of acute medication and healthcare services within the last year. Estimated prices are adjusted for the year 2021 and expressed in Euros. We did not include expenses for prophylactic treatment as this has previously been determined to be a very minor contributor of total costs  and during the time of data collection the CGRP-antibodies were not available. For direct cost of acute treatment, only patients with attacks within the last year were included. In Denmark, oxygen is paid for by the hospital, and delivered to the patients through sub-contractors. Currently the cost of oxygen is a fixed daily price. We estimated rental time of the equipment based on bout duration and added 60 days for return in the eCH population. In Denmark, the prices on drugs may vary on a weekly basis. Here, we used the prices for the cheapest option in the 2nd week of March 2021. Number of units used per day was estimated by attack frequency and self-reported percentages of attacks treated with a given treatment.
The indirect cost of illness was calculated following an incidence-based bottom-up approach. In the indirect cost analysis, we included absenteeism (sick days and disability pension) but not presenteeism. Participants could choose not to share their salary. If these patients reported sick days, their salary was assumed equivalent to other patients with the same education level. Participants could indicate if the fulltime disability pension had been approved due to CH, and only patients who indicated this were included in the indirect cost analysis. In Denmark, the compensation rate for part-time disability depends upon the salary and the reduction of working hours. We did not have access to the exact reduction hours and therefore assumed a work week for the part-time disabled of 20 h and an hourly wage of 26.7 € including pension. We could not determine if the part-time disability pension was approved due to CH or to comorbidities, but it is assumed that CH at least in part contributed to the decision.
R 3.6.1 and Rstudio 1.2.5001 were used for statistically analysis. Descriptive data is presented as mean (SD) or as a numeric (percentage) distribution. To compare categorical variables across categories the chi-square test was used and to compare continuous variables we applied one-way ANOVA or a two-sample t-test. Bonferroni correction was applied to the impact on everyday life in Fig. 3. Logistic regression (GLM function in R) was used to investigate the potential association between disability pension and clinical or demographic factors. We explored the literature on sociodemographic and CH specific factors of receiving disability pension and three variables was selected: sex, educational level and phenotype (cCH or eCH). We further explored the relationship between age of CH onset and disability pension because it is potential confounder of highest achieved education. Regarding self-rated health we applied an ordinal logistic regression using the “polr”-function in R. In order to increase power, we dichotomized participants responding poor or very poor and good or very good. We aimed to investigate phenotype on self-rated health, and we chose to control for sex and occupational status. No power calculation was preformed since we already publish the primary sleep analysis.
Registrations and approval
The Capital Region of Denmark Ethical Committee approved the study (H-2–2012-016) as part of a sleep CH-study . After this study was completed the survey did not need further formal approval from the ethics committee (file-number: 17008910). Patients gave informed oral and written consent according to the Helsinki declaration.
In total, 600 participants completed both the questionnaire and the semi-structured interview. Response rates were 400 out of 645 (62%) for patients and 200 out of 328 (61%) for controls. 253 participants were diagnosed with eCH and 146 with cCH. At time of interview one patient could not be classified as eCH or cCH (first bout) and was excluded from sub-analyses. Patients in bout, 124 out of 253 eCH patients (49%), were defined as having one or more attacks within the last month. In a previous publication from the same patient group  we found that male patients constituted a significantly larger part in the episodic group compared to the chronic group, respectively 182 out of 253 eCH patients (72%) and 86 out of 146 cCH patients (59%). The patients were 46.2 ± 11.5 years and had an average 3.6 ± 2.3 attacks/day. The controls were 44.7 ± 13.1 years and 133 (67%) were male. See Table 1 for further demographics. Pain intensity of usual attacks was rated severe or very severe by 95% of patients. Details regarding sleep, lifestyle, comorbidities, diagnostic factors and treatment have previously been published [12,13,14, 16].
Impact on self-rated health
Health ratings are visualized in Fig. 2. Health was rated as poor/very poor by one-fifth of the eCH patients in bout compared to more than one-third of the cCH patients (26 out of 127 (20%) vs 49 out of 144 (34%), p = 0.0009). Only, 2 (1%) of the controls and 11 (9%) of the eCH patients in remission rated their health as poor/very poor (p = 0.002). In general, self-rated wellbeing followed the same pattern as self-rated health. In those 57 eCH patients who had been in remission over one year only 3 (5%) reported their health as poor/very poor.
Compared to a cCH patient, the odds to rate health as good/very good were 3 times higher for an eCH patient in remission (OR 3.22, 95%CI 1.90–5.47, p < 0.001) and 10 times higher for a control (OR 10.10, 95%CI 5.29–18.79. p < 0.001) when correcting for occupation and sex. The eCH patients in bout had 1.6 higher odds of rating their health as good or very good compared to cCH patients, but the difference was not significant (OR 1.57, 95%CI 0.96–2.57, p = 0.074).
Impact on social and family life
Overall, being restricted in everyday life was reported by 234 out of 253 eCH patients (92%) during bout and 143 out of 146 (98%) cCH patients. In remission, 37 out of 253 eCH patients (15%) were restricted due to CH.
The majority (71%) of all the participants were married or living with a partner and marital status was evenly distributed among eCH patients, cCH patients, and controls (p = 0.104). Although there was an equal distribution of marital status, 18 eCH patients (7%) and 17 cCH patients (12%) reported being single as result of CH. In the eCH population, 54 (21%) described themselves as being dependent on family and friends due to CH compared to 70 (48%) cCH patients.
The decision of becoming a parent was impacted by CH in 16 eCH patients. Of these, 7 patients (3%) completely rejected having children and 9 patients (4%) chose not to have additional children. In the chronic group 11 patients (8%) discarded having children altogether and an additional 21 (14%) limited the number of children due to CH.
Within the last 10 years, 35 eCH patients (14%) and 56 cCH patients (38%) reported reduced ability to live a normal family-life. During a CH attack, the ability to perform normal household activities was reduced by 87% and participation in family social activities was on average reduced by 85%. The effects during the attack was similar among eCH and cCH patients.
Impact on professional life
In total, 158 CH patients had suffered from CH for less than 10 years and hereof 52 patients (42%) reported that the CH debut had a negative impact on their work-life (Table 2). Among all patients, 157 patients (39%) reported that CH impacted their work life and within the last 10 years 94 patients (24%) lost a job exclusively or partly due to CH. In comparison only 3 (2%) in the control group had lost a job during the last decade. Onset of CH before the age of 20 years did not affect educational level compared to patients with an onset in the second or third decade (Table 3).
In total, 52 patients (13%) were on full time disability pension and hereof 34 (64%) reported that CH was the deciding factor in the application and approval of the disability pension. Altogether, fulltime disability pension was significantly more frequent in cCH patients compared to eCH patients (28 cCH patients (19%) vs 24 eCH patients (9%), p = 0.007). Disability pension due to CH, was 5 times more likely for cCH patients compared to eCH patients (N = 400, OR 5.0, 95%CI 2.3–10.9, p < 0.001) in a logistics regression analysis when correcting for age, gender, highest achieved education and comorbidities (psychiatric and somatic). A bachelor or master’s degree was obtained by 10 patients (29%) out of 34 patients who received disability pension due to CH compared to only 3 patients (16%) out of 19 of patients who received disability due to other disease.
Absence due to sick days within the last year due to CH were recorded by 120 patients (57%) out of the 210 employed patients (full/part-time or self-employed). Among currently employed participants, cCH patients had 31.9 ± 68.5 annual sick days (N = 48), eCH patients had 13.6 ± 23.8 (N = 165), and controls had 4.1 ± 9.3 (N = 200), p < 0.001. If excluding CH related absenteeism, cCH patients had 6.9 additional sick days compared to the control group whereas the eCH patients had 1.5 more sick days than controls (p = 0.011). Only, 19 patients (9%) had more than 30 annual sick days. Regarding presenteeism, CH patients rated the ability to work as 7.2 ± 2.9 (N = 213) on a 11-point rating scale during periods with attacks whereas controls generally rated their productivity at work as 0.7 ± 1.8. Thus, the overall reduction in productivity amounts to 65% in comparison to the control group.
Direct and indirect cost
The direct and indirect costs are summarized for both eCH and cCH patients in Table 4. In the annual direct cost calculation, cCH patients were on average 6,395 € more costly compared the eCH patients (p < 0.001). Acute treatment with triptans and oxygen accounted annually for 3,619 ± 9,100 € per CH patient. Sumatriptan injection was the most expensive acute treatment, and in the group using this treatment, within the last year (n = 136) the average expense was 8,106 ± 13,946 € per patient. Whereas oxygen was used by 270 patients within the last year and the average cost here was 803 ± 411 € per patient receiving the treatment.
Another direct cost was the out-patient treatment. Within the last year, 166 patients (42%) had 2.3 ± 2.1 visits in a hospital-based out-patient clinic and 110 patients (28%) reported visits at a practicing neurologist and these patients reported a mean of 2.7 ± 2.6 visits. Additionally, 185 patients (46%) visited their general practitioner regarding CH treatment. Outside office hours, 59 (15%) patients reported visits to the emergency room or an on-call general practitioner for acute consults and herein 10 (17%) patients visited the emergency room more than two times. Within the last year 275 patients received out-patient treatment and the mean out-patient healthcare services amounted to 873 ± 1, 096 €. The mean annual cost of in-patient treatment 6,213 ± 7,227 € but only 55 patients reported hospitalization within the last year Table 4.
In the indirect cost calculation, cCH patients were on averages 8,240 € more expensive annually compared to eCH patients (p < 0.001).
CH impacts all investigated aspects of everyday life, especially in the chronic subgroup (Fig. 3). Not unexpectedly, health was rated significantly worse in periods with attacks compared to periods without attacks and to controls, but we could also demonstrate a significant burden for the patients in remission compared to controls. Finally, amongst the 400 CH patients we also identified a mean annual direct cost of 5178 €/patient and substantial loss of productivity resulting in a higher mean annual indirect cost of 6561 €/patient.
Self-rated health was significantly reduced in periods with attacks and cCH patients had ten-fold lower odds of rating their health as good or very good compared to controls. Even eCH patients who had been out of bout for more than a year did not rate their health as good as the controls. Self-rated health is an important predictor and strongly associated with increased mortality . CH have been associated with an increased suicidality  and an unhealthy lifestyle increasing the risk of cardiovascular diseases . The combined increased mortality risk should be taken serious by physicians treating CH patients. We unfortunately did not investigate the suicidality in the present study. Self-rated health was in part restored in remission periods but still not equal to the control group. The attack burden, but also comorbidities such as depression, anxiety and suicidality, are eased but still reported during remission [23, 24]. In addition, we found that CH influences many eCH patients when taking important life decisions, such as having (more) children, and their professional life was impacted by job loss and passing up projects at work. The pronounced effect on personal and professional life is in line with previous publications [4, 18, 25, 26]. Therefore, we put forward the argument that eCH, also, is a chronically disabling illness despite the cyclic nature of the bouts, at least for this patient population recruited from a hospital-based headache center. Current preventative is limited by targeting the bout once it occurs whereas the ideal preventative would prevent the occurrence of the bouts. Currently, physicians might reduce the anxiety by making the treatment plan during the remission.
In our cohort, 19% received full/part-time disability pension and this level was expected based on the general distribution for chronic pain patients in Denmark . Full-time disability pension was received by 13% of the CH population and although this is high it is in line with previous findings ranging from 8–15% [18, 28,29,30]. Of note, the CH population is better educated compared to the general population receiving disability pension, in our cohort 29% had a bachelor or master degree and in the general disability pension population this only accounted for 13% . This was also confirmed by another Scandinavian study, in which the CH diagnosis reduced the effects of education on odds of receiving disability pension . This points to CH causing social drift, rather than social causation. The subgroup with early onset had a stronger affiliation to the job market compared to a later onset. This could indicate that disease severity worsens with later onset; however, this is heavily biased by the Danish social welfare system where it takes time to go through the bureaucratic motions of testing ability to work and hearings. Further, after a reform in 2013 the general rule is that permanent support, such as disability pension, cannot be granted before the age of 40 years. Education level seems relatively unaffected by CH  and we demonstrated that this was also true for the patients who debuted young. In patients who debuted in the last 10 years, 21% had experienced a job loss due to CH. In previous studies from Denmark, Italy and the USA, 10–17% of the patients had reported loss of a job due to CH [18, 29, 32] whereas this only occurred in 3% in a recent Korean study . It is worrying that the number of patients losing their job was unchanged from previous publications, however, in our cohort we may have more cCH patients compared to the previous cohorts . New treatment options are highly needed to change the trend of job loss due to CH.
As hypothesized, the described burden is much more pronounced in cCH compared eCH. For example, 11% of the eCH patients indicate that they are without job compared to almost half the cCH patients. Previously, it was found that CH patients had higher employment rates compared to their unaffected family relatives, but this study only included eCH patients. Sick days for employed patients and healthy controls were similar to previous findings in a registry study . Notably, the eCH patients have almost identical number of sick days as controls when excluding CH related sick days but the chronic patients who are employed have twice the amount of sick days. This could be due to higher degree of comorbidities even in the 33% of the chronic population that are still employed.
The direct and indirect cost of CH were high especially in cCH patients where the total cost was three times that of the eCH patients. The direct costs of eCH patients were slightly higher in a German study (1,819 €/half year vs 2,763 €/year) from 2011 . The Italian study from 2020 found a mean cost of 1755 € per bout but since the cost were calculated per bout the findings are not directly comparable to our study. The direct cost of the cCH patients (approximately 9000 €) was similar to the findings by the Italian group . However, the German study found a direct cost of 9073 € within 6 months, but they included high cost procedures as implantation with occipital nerve stimulation and alternative treatments such as massage which were not included in our cost-calculation. The bulk of the cost was attributed to triptans and this is a common denominator in the three studies [19, 32]. Considering the high cost associated with triptans it is important to consider that this cost might be out-weighed by the resultant increased work productivity consequently lowering the indirect cost of CH. Our dataset unfortunately does not allow us to explore this as we were unable to quantify the presenteeism.
The direct cost was in this study based on patient reported outcome, another strategy to investigate this could be via the pharmacy databases in Denmark. Applying different methods of estimating the costs are a strength as they will reduce the common method bias. The indirect cost can be difficult to compare between the studies as there are both methodological and structural differences in social welfare systems. In our analysis we included part- and fulltime disability pensions as an indirect cost as we have no better way to estimate the productivity loss. The imprecisions in the evaluation of the indirect costs are stated as assumptions in the method section. The total indirect cost also includes presenteeism, rehabilitation, the work absence for the spouse and other costs . This is of course a limitation to the final output as generally the indirect cost is hard to quantify. However, similar rates of part-time disability pension was found in another registry study . The Danish welfare system is characterized by high redistribution of income and therefore we believe the human capital approach is the best fit even if it tends to overestimate the cost .
Our data is limited due to its cross-sectional nature, self-reports and recruitment from a tertiary headache center. The high rate of CCH patients reflects inclusion primarily form a specialized clinic and the results might not be representative for the entire CH population in Denmark. Another limitation is that we used validated health surveys, and did not investigate the emotional burden, the reason for this was the questionnaire already being quite comprehensive. Also, our control group was more educated than the patient groups and this might bias the health ratings . The strengths being the largest population of validated CH patients diagnosed according to the ICHD-criteria, unbiased to burden alone due to a very broad questionnaire and where both personal and societal burden are explored. It is important to notice that our results have a high variance indicating for some, even a short cluster period may have devastating effects on career and/or family life whereas others are relatively unaffected in their everyday life by cCH. This may depend on attack frequency, treatment response, social network, and education, and still other factors. The treatment response for this population has been published separately .
In conclusion, CH affects the patients significantly on both an economic and personal level. The chronic patients are much more affected in everyday life and costly than in the episodic patients. As expected eCH patients are less affected in remission than in bout, however, eCH patients in remission are still limited in important life and career choices. Therefore, we argue that eCH, also, is a chronically disabling illness despite the cyclic nature of the bouts. Hopefully, new emerging treatments will ease this for patients and society.
Availability of data and materials
The Danish Cluster Headache Survey contains sensitive information and can consequently not be shared in full form according to Danish data protection law. Deidentified data that underlie the results of this article can be shared on request.
Episodic cluster Headache
Chronic Cluster Headache;
Confidence interval (95%)
Manzoni GC, Micieli G, Granella F, Tassorelli C, Zanferrari C, Cavallini A (1991) Cluster Headache Course Over Ten Years in 189 Patients. Cephalalgia 11(4):169–174. https://doi.org/10.1046/j.1468-2982.1991.1104169.x
Barloese M, Lund N, Petersen A, Rasmussen M, Jennum P, Jensen R (2015) Sleep and chronobiology in cluster headache. Cephalalgia 35(11):969–978. https://doi.org/10.1177/0333102414564892
Kim BS, Chung PW, Kim BK et al (2020) The impact of remission and coexisting migraine on anxiety and depression in cluster headache. J Headache Pain 21(1):58. https://doi.org/10.1186/s10194-020-01120-7
Pohl H, Gantenbein AR, Sandor PS, Schoenen J, Andrée C (2020) Interictal Burden of Cluster Headache: Results of the EUROLIGHT Cluster Headache Project, an Internet-Based, Cross-Sectional Study of People With Cluster Headache. Headache 60(2):360–369. https://doi.org/10.1111/head.13711
Lund NLT, Snoer AH, Petersen AS et al (2019) Disturbed sleep in cluster headache is not the result of transient processes associated with the cluster period. Eur J Neurol 26(2):290–298. https://doi.org/10.1111/ene.13820
Pedersen AS, Snoer A, Barloese M, Petersen A, Jensen RH (2021) Prevalence of pre-cluster symptoms in episodic cluster headache: Is it possible to predict an upcoming bout? Cephalalgia 41(7):799–809. https://doi.org/10.1177/0333102421989255
Wei DYT, Yuan Ong JJ, Goadsby PJ (2018) Cluster headache: Epidemiology, pathophysiology, clinical features, and diagnosis. Ann Indian Acad Neurol 21(5):S3–S8. https://doi.org/10.4103/aian.AIAN_349_17
Manzoni GC, Taga A, Russo M, Torelli P (2016) Age of onset of episodic and chronic cluster headache – a review of a large case series from a single headache centre. J Headache Pain 17(1):44. https://doi.org/10.1186/s10194-016-0626-9
Olesen J (2018) Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38(1):1–211. https://doi.org/10.1177/0333102417738202
D’Amico D, Raggi A, Grazzi L, Lambru G (2020) Disability, Quality of Life, and Socioeconomic Burden of Cluster Headache: A Critical Review of Current Evidence and Future Perspectives. Headache 60(4):809–818. https://doi.org/10.1111/head.13784
Lund N, Barloese M, Petersen A, Haddock B, Jensen R (2017) Chronobiology differs between men and women with cluster headache, clinical phenotype does not. Neurology 88(11):1069–1076. https://doi.org/10.1212/WNL.0000000000003715
Frederiksen HH, Lund NL, Barloese MC, Petersen AS, Jensen RH (2020) Diagnostic delay of cluster headache: A cohort study from the Danish Cluster Headache Survey. Cephalalgia 40(1):49–56. https://doi.org/10.1177/0333102419863030
Petersen AS, Lund N, Jensen RH, Barloese M (2020) Real-life treatment of cluster headache in a tertiary headache center – results from the Danish Cluster Headache Survey. Cephalalgia 41(5):333102420970455. https://doi.org/10.1177/0333102420970455
Lund N, Petersen A, Snoer A, Jensen RH, Barloese M (2019) Cluster headache is associated with unhealthy lifestyle and lifestyle-related comorbid diseases: Results from the Danish Cluster Headache Survey. Cephalalgia 39(2):254–263. https://doi.org/10.1177/0333102418784751
Barloese M, Haddock B, Lund NT, Petersen A, Jensen R (2018) Chronorisk in cluster headache: A tool for individualised therapy? Cephalalgia 38(14):2058–2067. https://doi.org/10.1177/0333102418769955
Barloese MCJJ, Beske RP, Petersen AS, Haddock B, Lund N, Jensen RH (2020) Episodic and Chronic Cluster Headache: Differences in Family History, Traumatic Head Injury, and Chronorisk. Headache 60(3):515–525. https://doi.org/10.1111/head.13730
Lyngberg AC, Rasmussen BK, Jørgensen T, Jensen R (2005) Prognosis of migraine and tension-type headache: A population-based follow-up study. Neurology 65(4):580–585. https://doi.org/10.1212/01.wnl.0000172918.74999.8a
Jensen RM, Lyngberg A, Jensen RH (2007) Burden of cluster headache. Cephalalgia 27(6):535–541. https://doi.org/10.1111/j.1468-2982.2007.01330.x
Gaul C, Finken J, Biermann J et al (2011) Treatment costs and indirect costs of cluster headache: A health economics analysis. Cephalalgia 31(16):1664–1672. https://doi.org/10.1177/0333102411425866
Barloese MCJ, Jennum PJ, Lund NT, Jensen RH (2014) Sleep in cluster headache - beyond a temporal rapid eye movement relationship? Eur J Neurol 22(4):656-e40
DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P (2006) Mortality prediction with a single general self-rated health question: A meta-analysis. J Gen Intern Med 21(3):267–275. https://doi.org/10.1111/j.1525-1497.2005.00291.x
Koo BB, Bayoumi A, Albanna A et al (2021) Demoralization predicts suicidality in patients with cluster headache. J Headache Pain 22(1):28. https://doi.org/10.1186/s10194-021-01241-7
Ji Lee M, Cho SJ, Wook Park J et al (2019) Increased suicidality in patients with cluster headache. Cephalalgia 39(10):1249–1256. https://doi.org/10.1177/0333102419845660
Pohl H, Gantenbein AR, Sandor PS, Schoenen J, Andrée C (2020) Cluster headache and anxiety: Results of the EUROLIGHT cluster headache project – An Internet-based, cross-sectional study of people with cluster headache. Clin Transl Neurosci 4(1):2514183X2092595. https://doi.org/10.1177/2514183x20925956
Choi YJ, Kim BK, Chung PW et al (2018) Impact of cluster headache on employment status and job burden: A prospective cross-sectional multicenter study. J Headache Pain. 19(1):78. https://doi.org/10.1186/s10194-018-0911-x
Rozen TD, Fishman RS (2012) Female cluster headache in the United States of America: What are the gender differences?: Results from the United States Cluster Headache Survey. J Neurol Sci 317(1–2):17–28. https://doi.org/10.1016/j.jns.2012.03.006
Mathisen J, Jensen NK, Bjorner JB et al (2021) Disability pension among persons with chronic disease: Differential impact of a Danish policy reform. Eur J Public Health 31(1):186–192. https://doi.org/10.1093/eurpub/ckaa228
Jürgens TP, May A (2010) Chronischer clusterkopfschmerz: Was kostet die behandlung? Schmerz 24(3):221–225. https://doi.org/10.1007/s00482-010-0925-z
Rozen TD, Fishman RS (2012) Cluster headache in the United States of America: demographics, clinical characteristics, triggers, suicidality, and personal burden. Headache 52(1):99–113. https://doi.org/10.1111/j.1526-4610.2011.02028.x
Steinberg A, Josefsson P, Alexanderson K, Sjöstrand C (2019) Cluster headache: Prevalence, sickness absence, and disability pension in working ages in Sweden. Neurology 93(4):E404–E413. https://doi.org/10.1212/WNL.0000000000007787
Brun C, Bøggild H, Eshøj P (2003) Socioøkonomiske risikoindikatorer for førtidspension blandt erhvervsaktive danskere: En registerbaseret kohorteundersøgelse for perioden 1994–1998. Ugeskr Laeger 165(35):3315–3319
Negro A, Sciattella P, Spuntarelli V, Martelletti P, Mennini FS (2020) Direct and indirect costs of cluster headache: A prospective analysis in a tertiary level headache centre. J Headache Pain. 21(1):44. https://doi.org/10.1186/s10194-020-01115-4
Sjöstrand C, Russell MB, Ekbom K, Waldenlind E (2010) Familial cluster headache: Demographic patterns in affected and nonaffected. Headache 50(3):374–382. https://doi.org/10.1111/j.1526-4610.2009.01426.x
Sjöstrand C, Alexanderson K, Josefsson P, Steinberg A (2020) Sickness absence and disability pension days in patients with cluster headache and matched references. Neurology 94(21):e2213–e2221. https://doi.org/10.1212/WNL.0000000000009016
Yousefi M, AssariArani A, Sahabi B, Kazemnejad A, Fazaeli S (2014) Household Health Costs: Direct, Indirect and Intangible. Iran J Public Health 43(2):202 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450688/ Accessed 27 Apr 2022)
Van Den Hout WB (2010) The value of productivity: Human-capital versus friction-cost method. Ann Rheum Dis 69(SUPPL. 1):i89–i91. https://doi.org/10.1136/ard.2009.117150
Lahelma E, Pietiläinen O, Pentala-Nikulainen O, Helakorpi S, Rahkonen O (2019) 36-year trends in educational inequalities in self-rated health among Finnish adults. SSM - Popul Heal 9:100504. https://doi.org/10.1016/j.ssmph.2019.100504
The authors thank Christina Haurum, cand.polit, for valuable advice on the cost calculations. The authors thank all study participants for contributing data to the survey and study nurse Mette Frank Fisker for acquisition of data.
Ethics approval and consent to participate
The Capital Region of Denmark Ethical Committee approved the study (H-2–2012-016) as part of a sleep CH-study . After this study was completed the survey did not need further formal approval from the ethics committee (file-number: 17008910). Patients gave informed oral and written consent according to the Helsinki declaration.
Consent for publication
ASP: Current sub-investigator in trial for Lundbeck. Previous sub-investigator in trials for Eli-Lilly, and CCH pharmaceuticals. NL reports no disclosures. AS: Previous sub-investigator in trial for Lundbeck. AS was working as a MD in the Danish Headache Center at time of drafting the paper but is currently employed by Lundbeck Pharma (since 1.FEB.2022). She approved the manuscript but has not made any changes since working at Lundbeck Pharma. Previous sub-investigator in trial for Eli-Lilly. RHJ: Lectures for Pfizer, Eli-Lilly, Merck, TEVA, Novartis, Lundbeck and Allergan. Investigator in clinical trials with Eli-Lilly, Novartis and Lundbeck. MB reports no disclosures.
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Petersen, A.S., Lund, N., Snoer, A. et al. The economic and personal burden of cluster headache: a controlled cross-sectional study. J Headache Pain 23, 58 (2022). https://doi.org/10.1186/s10194-022-01427-7
- Burden of disease
- Cluster headache
- Quality of life
- Direct cost
- Indirect cost